Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Basit Öğe Kaydı
dc.contributor.authorTolaney, Sara M.
dc.contributor.authorJiang, Zefei
dc.contributor.authorZhang, Qingyuan
dc.contributor.authorBarroso-Sousa, Romualdo
dc.contributor.authorPark, Yeon Hee
dc.contributor.authorRimawi, Mothaffar F.
dc.contributor.authorSaura Manich, Cristina
dc.contributor.authorSchneeweiss, Andreas
dc.contributor.authorToi, Masakazu
dc.contributor.authorChae, Yee Soo
dc.contributor.authorKemal, Yasemin
dc.contributor.authorChaudhari, Mukesh
dc.contributor.authorYamashita, Toshinari
dc.contributor.authorCasalnuovo, Monica
dc.contributor.authorDanso, Michael A.
dc.contributor.authorLiu, Jie
dc.contributor.authorShetty, Jagdish
dc.contributor.authorHerbolsheimer, Pia Maarit
dc.contributor.authorLoibl, Sibylle
dc.date.accessioned2025-08-14T17:32:44Z
dc.date.available2025-08-14T17:32:44Z
dc.date.issued2025
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstract...
dc.description.sponsorshipFunding agency : AstraZeneca ; Daiichi Sankyo Company Limited.
dc.identifier.citationTolaney, S. M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y. H., Rimawi, M. F., ... & Loibl, S. (2025). Trastuzumab deruxtecan (T-DXd)+ pertuzumab (P) vs taxane+ trastuzumab+ pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. 10.1200/JCO.2025.43.17_suppl.LBA1008
dc.identifier.doi10.1200/JCO.2025.43.17_suppl.LBA1008
dc.identifier.endpageLBA1008
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue17_SUPPL
dc.identifier.startpageLBA1008
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5879
dc.identifier.volume43
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorKemal, Yasemin
dc.language.isoen
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.titleTrastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu